JPWO2021173740A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021173740A5 JPWO2021173740A5 JP2022550934A JP2022550934A JPWO2021173740A5 JP WO2021173740 A5 JPWO2021173740 A5 JP WO2021173740A5 JP 2022550934 A JP2022550934 A JP 2022550934A JP 2022550934 A JP2022550934 A JP 2022550934A JP WO2021173740 A5 JPWO2021173740 A5 JP WO2021173740A5
- Authority
- JP
- Japan
- Prior art keywords
- fenebrutinib
- subject
- acceptable salt
- pharmaceutically acceptable
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982872P | 2020-02-28 | 2020-02-28 | |
| US62/982,872 | 2020-02-28 | ||
| US202063051756P | 2020-07-14 | 2020-07-14 | |
| US63/051,756 | 2020-07-14 | ||
| PCT/US2021/019502 WO2021173740A1 (en) | 2020-02-28 | 2021-02-25 | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515528A JP2023515528A (ja) | 2023-04-13 |
| JPWO2021173740A5 true JPWO2021173740A5 (https=) | 2024-03-04 |
| JP2023515528A5 JP2023515528A5 (https=) | 2024-03-04 |
Family
ID=74885089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550934A Withdrawn JP2023515528A (ja) | 2020-02-28 | 2021-02-25 | ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230091561A1 (https=) |
| EP (1) | EP4110339A1 (https=) |
| JP (1) | JP2023515528A (https=) |
| KR (1) | KR20220148826A (https=) |
| CN (1) | CN115175682A (https=) |
| AU (1) | AU2021227674A1 (https=) |
| BR (1) | BR112022017102A2 (https=) |
| CA (1) | CA3170685A1 (https=) |
| CL (1) | CL2022002317A1 (https=) |
| IL (1) | IL295476A (https=) |
| MX (1) | MX2022010513A (https=) |
| TW (1) | TWI899163B (https=) |
| WO (1) | WO2021173740A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021249129A1 (en) | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP4732904A2 (en) * | 2015-10-06 | 2026-04-29 | F. Hoffmann-La Roche AG | Method for treating multiple sclerosis |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN110382052A (zh) * | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
| AU2021249129A1 (en) * | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
-
2021
- 2021-02-25 MX MX2022010513A patent/MX2022010513A/es unknown
- 2021-02-25 CN CN202180017387.XA patent/CN115175682A/zh active Pending
- 2021-02-25 TW TW110106714A patent/TWI899163B/zh active
- 2021-02-25 BR BR112022017102A patent/BR112022017102A2/pt unknown
- 2021-02-25 EP EP21712677.0A patent/EP4110339A1/en active Pending
- 2021-02-25 CA CA3170685A patent/CA3170685A1/en active Pending
- 2021-02-25 US US17/905,121 patent/US20230091561A1/en active Pending
- 2021-02-25 IL IL295476A patent/IL295476A/en unknown
- 2021-02-25 WO PCT/US2021/019502 patent/WO2021173740A1/en not_active Ceased
- 2021-02-25 JP JP2022550934A patent/JP2023515528A/ja not_active Withdrawn
- 2021-02-25 KR KR1020227030440A patent/KR20220148826A/ko active Pending
- 2021-02-25 AU AU2021227674A patent/AU2021227674A1/en active Pending
-
2022
- 2022-08-24 CL CL2022002317A patent/CL2022002317A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019203448B2 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| JP7183355B2 (ja) | 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法 | |
| CN103068398B (zh) | 丹参组合物在制备用于冠心病二级预防的药物中的用途 | |
| RU2488392C2 (ru) | Лечение агонистом мелатонина | |
| EP3206682B1 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| CN113692277B (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
| JP2023181398A (ja) | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 | |
| JP2025507156A (ja) | 処置方法 | |
| CN106714819A (zh) | 治疗普拉德‑威利综合征的方法 | |
| CN112638378A (zh) | 用于根除幽门螺杆菌的组合物 | |
| TW200423932A (en) | Combination of a PDE IV inhibitor and a TNF-alpha antagonist | |
| JP2012518019A5 (https=) | ||
| JPH07505646A (ja) | 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト | |
| CN115515590A (zh) | 马赛替尼用于治疗多发性硬化患者亚群 | |
| JPWO2021173740A5 (https=) | ||
| KR20030051812A (ko) | 불안 장애의 치료 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| EP0694299A1 (en) | The use of( a) bicycloheptane derivative(s) | |
| JPWO2021202825A5 (https=) | ||
| CN106660936A (zh) | 用于治疗adhd的方法和达斯曲林(dasotraline)组合物 | |
| US20240277662A1 (en) | Administration of a Compound to Individuals with Hepatic Impairment | |
| WO2025152934A1 (en) | Method for treating alzheimer's disease | |
| RU2283097C2 (ru) | Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны | |
| JPWO2022051575A5 (https=) | ||
| WO2006038084A1 (en) | Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression |